Filing Flows › Biocryst Pharmaceuticals (BCRX) › Q2 2026 › vs Q1 2026
Biocryst Pharmaceuticals (BCRX) Q2 2026 vs Q1 2026 (quarter over quarter)
Biocryst Pharmaceuticals's revenue rose $61.8M (+40%) from $156M in Q1 2026 to $218M in Q2 2026. Operating margin 45.1% against -448.6% (+493.7 pts).
Biocryst Pharmaceuticals, Q2 2026: revenue $218M (+34% year over year), operating margin 45.1%, net earnings $78.4M, operating cash flow $104M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 45.1% | -448.6% | +493.7 pts |
| Net margin | 35.9% | -461.5% | +497.4 pts |
| Free cash flow margin | 47.7% | -39.8% | +87.5 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $218M | $156M | $61.8M | +40% |
| Operating profit | $98.5M | −$702M | $800M | — |
| Costs & expenses | $120M | $858M | −$738M | -86% |
| Pre-tax earnings | $79.5M | −$721M | $800M | — |
| Other expense, net | $19.0M | $19.2M | −$219K | -1% |
| Cost of revenue | $3.8M | $5.4M | −$1.5M | -29% |
| Research & development | $52.0M | $60.3M | −$8.3M | -14% |
| SG&A | $64.0M | $94.6M | −$30.6M | -32% |
| Net earnings | $78.4M | −$722M | $800M | — |
| Income tax | $1.1M | $1.0M | $75K | +7% |
| Depreciation & amortization | $513K | $1.1M | −$548K | -52% |
| Share-based compensation | $14.7M | $16.0M | −$1.3M | -8% |
| Working capital & other | $10.7M | $643M | −$632M | -98% |
| Operating cash flow | $104M | −$61.8M | $166M | — |
| Free cash flow (OCF − capex) | $104M | −$62.2M | $166M | — |
| Capital expenditures | $209K | $403K | −$194K | -48% |
Questions
How much did Biocryst Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Biocryst Pharmaceuticals's revenue rose $61.8M (+40%) from $156M in Q1 2026 to $218M in Q2 2026. Operating margin 45.1% against -448.6% (+493.7 pts).